• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Rockwell Medical Inc.

    1/2/25 3:18:26 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001599219
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ROCKWELL MEDICAL, INC.
    SEC File Number
    000-23661
    Address of Issuer
    30142 WIXOM ROAD
    WIXOM
    MICHIGAN
    48393
    Phone
    8004493353
    Name of Person for Whose Account the Securities are To Be Sold
    Strobeck Mark
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Raymond James & Associates
    880 Carillon Parkway
    St. Petersburg � FL � 33716
    21634445.003231880601/02/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/17/2024Vesting of RSU'sIssuerCheckbox not checked2773303/17/2024RSU Vesting

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    01/02/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/30/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Maressia Rooks-Bailey, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Mark Strobeck

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Strobeck Mark sold $7,480 worth of shares (6,926 units at $1.08), decreasing direct ownership by 5% to 124,678 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/2/25 6:06:41 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, FINANCE AND CFO Neri Jesse sold $975 worth of shares (886 units at $1.10), decreasing direct ownership by 3% to 30,000 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/2/25 6:05:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

      4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

      4/15/25 2:02:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      11/14/24 5:17:40 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

      SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      2/14/24 2:31:02 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

      SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

      9/6/23 4:49:44 PM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Financials

    Live finance-specific insights

    See more
    • Rockwell Medical Announces First Quarter 2025 Results

      Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit of $3.0 million for the first quarter of 2025, in line with the same period in 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three months ended March 31, 2025. "During the first quarter, we continued to diversify our customer base with some of the leading regional, national and global hemodialysis provi

      5/12/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical to Release First Quarter 2025 Results on Monday, May 12, 2025

      Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2025 on Monday, May 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, May 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Results Speakers:

      4/14/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results

      Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports record gross profit for the third year in a row, generating $17.5 million in 2024, a 101% increase over 2023. Reports record net sales for the third year in a row, generating $101.5 million in 2024, a 21% increase over 2023. Net sales for the fourth quarter of 2024 were $24.7 million, a 12% increase over the same period in 2023. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and o

      3/20/25 6:00:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Universal Display Corporation Announces the Appointment of New Board Members

      Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

      3/7/24 4:05:00 PM ET
      $BDN
      $NOTV
      $OLED
      $RMTI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Rockwell Medical Appoints Joan Lau, Ph.D. to the Company's Board of Directors

      Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

      10/17/23 6:00:00 AM ET
      $BDN
      $RMTI
      $RCOR
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer

      WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci

      6/24/22 8:56:00 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RMTI
    SEC Filings

    See more
    • Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

      Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

      11/14/24 7:56:29 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

      1/18/22 10:00:06 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

      HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

      9/7/21 6:17:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:21:47 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rockwell Medical Inc.

      10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 7:00:44 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rockwell Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

      5/12/25 6:18:10 AM ET
      $RMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care